Abstract
Osimertinib (Osi) has been a standard treatment for untreated patients (pts) with non-small-cell lung cancer (NSCLC) harboring an EGFR mutation. Previous studies showed that the addition of anti-VEGF inhibitors to erlotinib prolonged progression-free survival (PFS) in EGFR mutated non-squamous NSCLC (Ns-NSCLC) pts. This phase II, open-label, randomized trial was conducted to compare Osi plus bevacizumab (Bev) with Osi monotherapy for untreated pts with advanced EGFR mutated Ns-NSCLC.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have